Lyme Disease Truth: Dr. Christian Perronne

October 14, 2026

Dec. 2025

Approx. 50 Min

🔷 Christian Perronne
Infectious Disease Specialist, former Head of Department at the Garches University Hospital

Author of several books, including most recently “The Awakening, 4 Years Later” (co-written with Stéphane Chatry, Guy Tredaniel Publishers)

________________

**Comment**

By using the closed caption setting and translating the transcript to English, you can listen to Dr. Perronne’s take on the current state of Lymeland and how mainstream medicine continues to deny chronic Lyme disease.

For more:

For a bird’s eye view of the entire Lyme debacle: https://madisonarealymesupportgroup.com/2020/09/25/why-should-we-care-about-lyme-disease-a-colorful-tale-of-government-conflicts-of-interest-probable-bioweaponization-and-pathogen-complexity/

For an excellent article on why the PTLDS title is fraudulent and does not explain why many remain ill: https://madisonarealymesupportgroup.com/2020/08/13/slyme-an-interview-we-need-to-drop-the-term-ptld-like-a-bad-habit/

Category:

Lyme, Uncategorized

Comments Off on Lyme Disease Truth: Dr. Christian Perronne

ACTION: Comment to HHS on EMF Health Effects Until Oct. 21, 2026

https://read.sayerji.com/p/secretary-kennedy-asked-for-the-evidence?

Secretary Kennedy Asked for the Evidence on EMF. Here Are 1,009 Studies.

HHS has opened the first federal health inquiry into wireless radiation in a decade. Your opportunity to comment and make a difference is now.

Sayer Ji

Oct 09, 2026

Article Excerpts:

For more than fifteen years, GreenMedInfo has indexed the peer-reviewed literature on electromagnetic field exposure under a single heading: Electromagnetic Field Harms. As of this week, that page holds 1,009 research abstracts, tagged to 156 distinct health outcomes and 30 natural substances studied for protective effects. Every record links to its PubMed entry. Anyone can read it. Nobody in the federal government has ever been asked to.

Until now.

This article does three things. It explains, in plain language, what the index actually shows — including the parts that cut against the easy story. It explains why the timing matters, which comes down to a 1996 rulebook and a 2021 court decision that was never answered. And it shows you how to file a comment in five minutes, whether you are a parent with a story or a physician with a caseload.

The outcomes with the most studies behind them are not exotic. They are oxidative stress (167 abstracts), DNA damage (82), male infertility (44), lipid peroxidation (43), cognitive decline (38), cancers (34), low sperm quality (33), brain cancer (28), headache (20), sleep disorders (15) and fatigue (14). Further down the list: childhood leukemia, acoustic neuroma, salivary gland disease, hearing disorders, ALS, Alzheimer’s, autism spectrum disorders, birth defects, hypothyroidism, autoimmune disease. (See link for article)

_______________

**Comment**

Lyme/MSIDS patients need to take the deleterious health effects of EMF seriously as it compounds their symptoms and is a known ‘illness intensifier.’ I highly recommend this article as Ji corrects many details used by EMF supporters as well as shows you how to quickly file a comment on either your experience or evidence. Please take the time to do so. Deadline is October 21, 2026

For more:

Category:

Activism, EMF, research

Comments Off on ACTION: Comment to HHS on EMF Health Effects Until Oct. 21, 2026

153 Nations Just Voted For Permanent Emergency. The US ‘No’ Was About Something Else

https://read.sayerji.com/p/153-nations-just-voted-for-the-permanent?

BREAKING: 153 Nations Just Voted for the Permanent Emergency. The US “No” Was About Something Else.

Sayer Ji

Oct. 13, 2026

The UN’s pandemic declaration commits governments to counter health “misinformation” and never mentions freedom of expression, privacy or informed consent. The United States objected to other things.

Disclosure: I am a named plaintiff in Finn et al. v. Global Engagement Center (dismissed with prejudice on 28 July 2026) and the founder of Restore the First, the coalition the plaintiffs convened.

Article Excerpts:

On 12 October 2026 the UN General Assembly adopted a pandemic declaration by 153 votes to 3, with 2 abstentions (UN News). Paragraph 57 commits governments to “take measures to counter and address” health “misinformation, disinformation,” and to foster “trust in public health systems and authorities.” It defines neither term and never mentions freedom of expression, privacy or informed consent. The one government I can confirm dissociating from that commitment on the record, Italy, voted yes. The United States, which called the vote, did not raise it.

The declaration is non-binding. By “permanent emergency” I mean the argument of my white paper: an emergency architecture with no exit conditions. The declaration does not declare one. The question is what it leaves out.

The vocabulary is not new either: the amended International Health Regulations (IHR) already list “risk communication, including addressing misinformation and disinformation” among core capacities (conference text). Three things still make this the sentence to watch.

  • Wider than its method. “Take measures to counter and address” is the operative phrase. Nothing says the measures stop at education, and no paragraph says what they may not include.
  • No definitions, no referee. Italy, which voted yes, called “infodemic management, misinformation, disinformation, and stigmatization” “not the subject of an agreed definition.”
  • A medical choice as a target. “Countering vaccine hesitancy” sits inside the commitment. The declaration never mentions informed consent.

The declaration has no emergency thresholds, no sunset clause, no review by courts or legislatures, no list of rights that cannot be suspended and no informed-consent guarantee.

In spring 2022, nearly 140,000 of its advocates emailed and called their representatives in support of a bill to defund the WHO, and 46 lawmakers signed on within a month.

That withdrawal rests on an executive order, which a future president could reverse. Stand for Health Freedom is now asking Americans to back H.R. 3839, Rep. Tim Burchett’s bill to make the exit permanent in law, because “without a law, the U.S. could rejoin the WHO at any time without Congress’ approval.” [standforhealthfreedom]

Take action: Tell your representative to cosponsor H.R. 3839 →[standforhealthfreedom]

(See link for article)

__________________

**Comment**

The ‘powers that be’ are working overtime to give the illusion the U.S. is outside the power of the WHO’s pandemic treaty when the devil’s in the fine print. Nothing’s changed and can revert right back to overarching tyranny anytime someone declares a ‘pandemic’ emergency.

The “no” vote is a position, not a reform.


Please remember this as you go here to listen to Nicolas Hulscher explain how this declaration pushes ‘fast-tracked vaccines’ within 100 days, and will combat ‘vaccine’ hesitancy. Scientific censorship remains on the menu as well as lockdowns, ‘vaccine’ mandates, and other sweeping worthless health measures like mask mandates.

The news is not good, friends.

Seems nothing was learned from COVID.

For more:

The Plan has been in the works for decades and is quietly being implemented globally.

Category:

Activism

Comments Off on 153 Nations Just Voted For Permanent Emergency. The US ‘No’ Was About Something Else

Evidentiary Review: Mebendazole, Fenbendazole and Ivermectin for Astrocytoma

https://popularrationalism.substack.com/p/evidentiary-review-mebendazole-fenbendazole?

EVIDENTIARY REVIEW: Mebendazole Fenbendazole and Ivermectin for Astrocytoma

Evidence as of October 12, 2026

James Lyons-Weiler, PhD

Article Excerpts:

Mebendazole has reached human brain-tumor trials, while the astrocytoma case for fenbendazole and ivermectin still rests chiefly on preclinical research. It then explains why current molecular diagnoses matter, especially the distinction between IDH-mutant astrocytoma and IDH-wildtype glioblastoma, and traces the experimental rationale from the original benzimidazole observations to newer studies in IDH-mutant and pediatric glioma models.

The clinical appraisal examines five mebendazole reports, separating dose-finding from efficacy testing and identifying what missing control groups, historical comparisons, post-treatment selection, and mixed diagnoses prevent us from concluding. The laboratory appraisal distinguishes fenbendazole from flubendazole, includes the published figure correction, and examines ivermectin’s mitochondrial and autophagy findings without treating a molecular mechanism as a clinical outcome. The final argument connects drug exposure, neurological and hepatic safety, disclosure, reproducibility, and meaningful endpoints to a concrete research program. The conclusion calls for controlled, independently auditable studies that can earn a therapeutic claim or retire it.

Doctors are being peppered with questions about a new category of drugs for use in cancer. A patient who asks whether mebendazole, fenbendazole, or ivermectin might help treat astrocytoma has asked a legitimate scientific question. The answer requires considerably more care than a declaration that these are antiparasitic drugs, because a molecule’s original indication does not determine every biological action it can exert. It also requires more care than a collection of favorable laboratory results, because an effect in cultured cells must survive a demanding sequence of tests before it can support a claim about a person with a brain tumor. The published record contains enough substance to justify serious investigation, and enough unresolved questions to make confident therapeutic promises premature.

The evidence reviewed here does not establish that institutions suppressed an effective astrocytoma treatment. It does establish that the decisive treatment comparisons remain incomplete. We should direct criticism toward that demonstrable gap and ask who will close it. Public and philanthropic funding can support trials whose value lies in answering a clinical question even when the eventual product offers limited commercial reward. Funding decisions should account for disease burden, biological plausibility, and the information a study can produce. Investigators and advocates should disclose relevant patents, equity, product sales, and referral arrangements, while sponsors should commit in advance to reporting unfavorable results.

A defensible next program would begin with molecularly characterized patient-derived models and independent replication across laboratories. It would test each candidate separately, then justify each proposed combination with concentration-response and interaction experiments. The investigators should include normal neural and hepatic systems to examine selectivity, use exposure ranges that a human development program could realistically investigate, and report failures alongside successes. For mebendazole, formulation and polymorph require explicit characterization. For every candidate, the relevant question concerns active, sustained exposure at the tumor site, which requires evidence beyond an administered dose or a transient concentration in plasma. (See link for article)

_______________

For more:

Category:

Cancer, research, Testing, Treatment

Comments Off on Evidentiary Review: Mebendazole, Fenbendazole and Ivermectin for Astrocytoma

Study: Tickborne Illness, Folate, Autism, PANS/PANDAS & FRAA

October 12, 2026

https://tickbootcamp.com/episode-595-can-lyme-affect-folate-in-the-brain-dr-lindsey-wells-on-autism-pans-pandas-fraa/

Episode 595: Can Lyme Affect Folate in the Brain? Dr. Lindsey Wells on Autism, PANS/PANDAS & FRAA

Lindsey_Wells_sq1

What if some of the depression, anxiety, brain fog, cognitive dysfunction, OCD, speech changes, and other neuropsychiatric symptoms experienced by people with Lyme and other vector-borne diseases involve more than the infection itself?

In this episode of the Tick Boot Camp Podcast, Matt Sabatello sits down with Dr. Lindsey Wells, ND, a Connecticut naturopathic physician whose work focuses heavily on children with Lyme Disease, PANS/PANDAS, autism spectrum disorder, neurodevelopmental conditions, and other vector-borne diseases.

The centerpiece of the conversation is Dr. Wells’ newly published research, “Folate Receptor Alpha Autoantibodies in Vector-Borne Disease Populations.”

Her study explored an intriguing question: could some people with Lyme disease, Bartonella, Babesia, or other vector-borne infections also have an immune-mediated problem that prevents enough folate from reaching the brain?

The findings open an important new area of investigation. (See link for article and interview)

_________________

**Comment**

The study found that nearly 62% of patients with tick borne illness tested positive for folate receptor alpha autoantibodies.

The study also found that Bartonella was the most common individual infection identified among FRAA-positive patients.

Important excerpt:

She discusses research suggesting that proteins associated with animal dairy may share similarities with folate receptor structures. Through a molecular mimicry mechanism, antibodies generated against those proteins could potentially cross-react with folate receptors.

Dr. Wells therefore commonly incorporates dairy removal when addressing FRAA-positive patients.

She also discusses clinical observations suggesting that FRAA levels can fluctuate and may rise during periods of infection or physiological stress.

Another important point is a routine folate blood test can not determine FRAA status. The FRAT Folate Receptor Autoantibody Test, a specialty blood test designed to detect autoantibodies to folate receptor alpha is required.

Dr. Wells has seen clinical improvements in these patients in anxiety, OCD, cognition, communication, and other neuropsch symptoms by using folinic acid (Leucovorin) as it utilizes another folate transport mechanism to deliver folate to the CNS.

Category:

Autism, Lyme, PANS, research, Supplements, Testing, Treatment

Comments Off on Study: Tickborne Illness, Folate, Autism, PANS/PANDAS & FRAA